Cover Image
市場調查報告書

異常血紅素症市場規模與預測:各類型 (α地中海型貧血、β地中海型貧血、鐮狀細胞貧血症、不穩定血紅素症) 、各治療 (輸血、鐵螫合物療法、其他) 、各診斷,及2015∼2022年趨勢分析

Hemoglobinopathies Market Size & Forecast By Type (Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases), By Therapy (Blood Transfusion, Iron Chelation Therapy, and Others), By Diagnosis And Trend Analysis From 2012 To 2022

出版商 Grand View Research, Inc. 商品編碼 355247
出版日期 內容資訊 英文 87 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
異常血紅素症市場規模與預測:各類型 (α地中海型貧血、β地中海型貧血、鐮狀細胞貧血症、不穩定血紅素症) 、各治療 (輸血、鐵螫合物療法、其他) 、各診斷,及2015∼2022年趨勢分析 Hemoglobinopathies Market Size & Forecast By Type (Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases), By Therapy (Blood Transfusion, Iron Chelation Therapy, and Others), By Diagnosis And Trend Analysis From 2012 To 2022
出版日期: 2016年02月22日 內容資訊: 英文 87 Pages
簡介

全球異常血紅素症市場,預計至2022年達到88億2,000萬美元。鐮狀細胞貧血症和地中海型貧血等異常血紅素症的罹患率上升有大幅影響。根據WHO,異常血紅素症在超越229個國家中有60%國家中影響新生兒的70%以上。

本報告提供全球異常血紅素症市場現狀與至2022年的成長預測,各類型、各治療、各診斷趨勢,以及主要企業的簡介等彙整。

第1章 調查方法與調查範圍

第2章 摘要整理

第3章 產業預測

  • 市場區隔
  • 市場規模與成長預測
  • 異常血紅素症:市場趨勢
    • 促進要素
    • 阻礙要素
  • 主要的機會分析
  • 產業分析:波特
  • PESTEL分析
  • 異常血紅素症:政府的法規
  • 需求差距分析
    • 罹患率
    • 治療效果
    • 跟治療的差距

第4章 各治療市場預測

  • 各治療市場佔有率
  • 地中海型貧血
  • 鐮狀細胞貧血症
  • 其他

第5章 各診斷預測

  • 各診斷市場佔有率
  • 地中海型貧血
  • 鐮狀細胞貧血症
  • 其他

第6章 各地區預測

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第7章 競爭環境

  • Gamida Cell
  • Alnylam Pharmaceuticals
  • Biogen Idec
  • Sangamo BioSciences Inc.
  • Genetix Pharmaceuticals/Bluebird Bio
  • Global Blood Therapeutics Inc.
  • Pfizer Inc.
  • Mast Therapeutics
  • Emmaus Life Sciences, Inc.
  • Prolong Pharmaceuticals
  • Celgene Corporation
  • HemaQuest Pharmaceuticals

圖表

目錄
Product Code: 978-1-68038-736-0

Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022 according to a new report by Grand View Research Inc. Rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant variation.

Prevalence of hemoglobinopathies is high in low-income countries such as Sub Saharan region and South East Asia. 85% of the affected population in the U.S. and Europe has ancestral base in these regions.

Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Thalassemia Data Collection Project and Registry and Surveillance System for Hemoglobinopathies (RuSH) projects were started in 2010 by the Centers for Disease Control and Prevention (CDC).

Low level of hygiene, insufficient healthcare infrastructure, and lesser awareness levels are some key factors attributing to increase in base of target population in low-income regions such as South East Asia, Mediterranean basin, and Africa.

Further key findings from the study suggest:

The market for Sickle Cell Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million in 2014. Rising prevalence of hemoglobinopathies and presence of strong product pipeline for sickle cell anemia such as HQK-1001 and Luspatercept are growth promoting factors of this market.

Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. It is estimated to grow at a CAGR of around 7.0%. Increasing awareness levels among people coupled with government programs such as the National Sickle Cell Disease Control Program conducted by the WHO in Africa are anticipated to enhance the usage rates for diagnostic tests pertaining to SCD.

Hydroxyurea was one of the dominating segments of the SCD therapy market owing to the presence of the FDA-approved drugs such as Droxia and Hydrea by Bristol Myers Squib. SCD. Thalassemia market holds an extensive product portfolio in pipeline and their expected commercialization is anticipated to drive market growth. For instance, The Ellis Lab is developing a gene therapy for SCD in collaboration with Dr. Victor Garcia

Blood tests including cell blood count and iron studies are the widely used techniques for diagnosis of thalassemia. On the other hand, pre-implant genetic testing is estimated to grow at lucrative growth rate over 8.5% in the next six years owing to rising base of health conscious population and increasing healthcare expenditure.

The market for blood transfusion was the largest with revenues valued at over USD 1,408.0 million in therapeutic segment owing to, high acceptance level of this treatment option and significant success rate. It is estimated that around 85% of infants below five years suffering from thalassemia die due to insufficient blood transfusion.

North America dominated the overall hemoglobinopathies market in terms of revenue in 2014 at over USD 1,212.0 million. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing are factors attributing to the major share of this market.

Asia Pacific market is expected to witness lucrative growth over the forecast period with a CAGR of over 10% owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives will enhance adoption rates for hemoglobinopathies diagnostics market.

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources
  • 1.4. Known, Unknown variables & target segment

Chapter 2. Executive Summary

Chapter 3. Hemoglobinopathies Industry Outlook

  • 3.1. Market segmentation
  • 3.2. Market size and growth prospects
  • 3.3. Hemoglobinopathies : Market dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.1. Market Restraint Analysis
  • 3.4. Key opportunity analysis, by type- 2014
  • 3.5. Industry analysis Porter's
  • 3.6. Hemoglobinopathies : PESTEL Analysis
  • 3.7. Hemoglobinopathies Market : Government Regulations
    • 3.7.1. Sickle Cell Disease(SCD) drug development
    • 3.7.2. Drug development for Thalassemia
  • 3.8. Hemoglobinopathies Market: Need Gap Analysis
    • 3.8.1. Prevalence
    • 3.8.2. Treatment efficacy
    • 3.8.3. Therapeutic gap

Chapter 4. Hemoglobinopathies Therapy Outlook

  • 4.1. Hemoglobinopathies market share by therapy, 2014 & 2022
  • 4.2. Thalassemia therapy
    • 4.2.1. Thalassemia therapy market, 2012-2022(USD Million)
    • 4.2.2. Alpha thalassemia therapy
      • 4.2.2.1. Alpha thalassemia therapy market, 2012-2022(USD Million)
    • 4.2.3. Beta thalassemia therapy
      • 4.2.3.1. Beta thalassemia therapy market, 2012-2022(USD Million)
  • 4.3. Sickle Cell Disease(SCD) therapy
    • 4.3.1. Sickle Cell Disease(SCD) therapy market, 2012-2022(USD Million)
  • 4.4. Other therapy
    • 4.4.1. Other haemoglobin variants therapy market, 2012-2022(USD Million)

Chapter 5. Hemoglobinopathies Diagnosis Outlook

  • 5.1. Hemoglobinopathies market share by diagnosis, 2014 & 2022
  • 5.2. Thalassemia diagnosis
    • 5.2.1. Thalassemia diagnosis market, 2012-2022(USD Million)
    • 5.2.2. Alpha thalassemia diagnosis
      • 5.2.2.1. Alpha thalassemia diagnosis market, 2012-2022(USD Million)
    • 5.2.3. Beta thalassemia diagnosis
      • 5.2.3.1. Beta thalassemia diagnosis market, 2012-2022(USD Million)
  • 5.3. Sickle Cell Disease(SCD) diagnosis
    • 5.3.1. Sickle Cell Disease(SCD) diagnosis market, 2012-2022(USD Million)
  • 5.4. Other hemoglobin variants
    • 5.4.1. Other haemoglobin variants market, 2012-2022(USD Million)

Chapter 6. Hemoglobinopathies Regional Outlook

  • 6.1. Hemoglobinopathies market Share by Region, 2014 & 2022
  • 6.2. North America
    • 6.2.2. U.S.
    • 6.2.4. Canada
  • 6.3. Europe
    • 6.3.1. Europe Hemoglobinopathies Market, 2012-2022(USD Million)
    • 6.3.2. UK
    • 6.3.3. UK Hemoglobinopathies Market, 2012-2022(USD Million)
    • 6.3.4. Germany
    • 6.3.5. Germany Hemoglobinopathies Market, 2012-2022(USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Hemoglobinopathies Market, 2012-2022(USD Million)
    • 6.4.2. Japan
    • 6.4.4. China
    • 6.4.5. China Hemoglobinopathies Market, 2012-2022(USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Hemoglobinopathies Market, 2012-2022(USD Million)
    • 6.5.2. Brazil
    • 6.5.3. Brazil Hemoglobinopathies Market, 2012-2022(USD Million)
    • 6.5.4. Mexico
    • 6.5.5. Mexico Hemoglobinopathies Market, 2012-2022(USD Million)
  • 6.6. MEA
    • 6.6.2. South Africa
    • 6.6.3. South Africa Hemoglobinopathies Market, 2012-2022(USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Gamida Cell
    • 7.1.1. Company Overview
    • 7.1.2. Financial Performance
    • 7.1.3. Product Benchmarking
    • 7.1.4. Strategic Initiatives
  • 7.2. Alnylam Pharmaceuticals
    • 7.2.1. Company Overview
    • 7.2.2. Financial Performance
    • 7.2.3. Product Benchmarking
    • 7.2.4. Strategic Initiatives
  • 7.3. Biogen Idec
    • 7.3.1. Company Overview
    • 7.3.2. Financial Performance
    • 7.3.3. Product Benchmarking
    • 7.3.4. Strategic Initiatives
  • 7.4. Sangamo BioSciences Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Financial Performance
    • 7.4.3. Product Benchmarking
    • 7.4.4. Strategic Initiatives
  • 7.5. Genetix Pharmaceuticals/Bluebird Bio
    • 7.5.1. Company Overview
    • 7.5.2. Financial Performance
    • 7.5.3. Product Benchmarking
    • 7.5.4. Strategic Initiatives
  • 7.6. Global Blood Therapeutics Inc.
    • 7.6.1. Company Overview
    • 7.6.2. Financial Performance
    • 7.6.3. Product Benchmarking
    • 7.6.4. Strategic Initiatives
  • 7.7. Pfizer Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Financial Performance
    • 7.7.3. Product Benchmarking
    • 7.7.4. Strategic Initiatives
  • 7.8. Mast Therapeutics
    • 7.8.1. Company Overview
    • 7.8.2. Financial Performance
    • 7.8.3. Product Benchmarking
    • 7.8.4. Strategic Initiatives
  • 7.9. Emmaus Life Sciences, Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Financial Performance
    • 7.9.3. Product Benchmarking
    • 7.9.4. Strategic Initiatives
  • 7.10. Prolong Pharmaceuticals
    • 7.10.1. Company Overview
    • 7.10.2. Financial Performance
    • 7.10.3. Product Benchmarking
    • 7.10.4. Strategic Initiatives
  • 7.11. Celgene Corporation
    • 7.11.1. Company Overview
    • 7.11.2. Financial Performance
    • 7.11.3. Product Benchmarking
    • 7.11.4. Strategic Initiatives
  • 7.12. HemaQuest Pharmaceuticals
    • 7.12.1. Company Overview
    • 7.12.2. Financial Performance
    • 7.12.3. Product Benchmarking
    • 7.12.4. Strategic Initiatives

List of Tables

  • TABLE 1: Hemoglobinopathies- Industry Snapshot & Key Buying Criteria, 2012 - 2022
  • TABLE 2: Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 3: Hemoglobinopathies market, by region, 2012 - 2022 (USD Million)
  • TABLE 4: Global Hemoglobinopathies- Key market driver analysis
  • TABLE 5: Normal human haemoglobins
  • TABLE 6: Sickle cell disease- Estimates in the U.S.
  • TABLE 7: Worldwide annual births with various hemoglobin disorders
  • TABLE 8: Product pipeline 28
  • TABLE 9: Hemoglobinopathies- Key market restraint analysis
  • TABLE 10: Ongoing FDA Orphan Grants for SCD
  • TABLE 11: Estimated reach of blood transfusion treatment for Beta-Thalassemia in WHO region
  • TABLE 12: Estimated reach of iron chelation treatment for Beta-thalassemia in WHO region
  • TABLE 13: North America hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 14: North America thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 15: North America thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 16: North America sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 17: North America sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 18: North America other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 19: North America other Hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 20: U.S. Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 21: U.S. thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 22: U.S. thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 23: U.S. sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 24: U.S. sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 25: U.S. other Hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 26: U.S. other Hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 27: Canada Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 28: Canada thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 29: Canada thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 30: Canada sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 31: Canada sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 32: Canada other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 33: Canada other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 34: Europe Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 35: Europe thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 36: Europe thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 37: Europe sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 38: Europe sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 39: Europe other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 40: Europe other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 41: UK Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 42: UK thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 43: UK thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 44: UK sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 45: UK sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 46: UK other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 47: UK. other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 48: Germany hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 49: Germany thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 50: Germany thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 51: Germany sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 52: Germany sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 53: Germany other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 54: Germany other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 55: Asia Pacific hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 56: Asia Pacific thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 57: Asia Pacific thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 58: Asia Pacific sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 59: Asia Pacific sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 60: Asia Pacific other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 61: Asia Pacific other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 62: Japan hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 63: Japan thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 64: Japan thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 65: Japan sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 66: Japan sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 67: Japan other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 68: Japan other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 69: China hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 70: China thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 71: China thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 72: China sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 73: China sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 74: China other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 75: China other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 76: Latin America hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 77: Latin America thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 78: Latin America thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 79: Latin America sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 80: Latin America sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 81: Latin America other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 82: Latin America other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 83: Brazil hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 84: Brazil thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 85: Brazil thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 86: Brazil sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 87: Brazil sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 88: Brazil other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 89: Brazil other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 90: Mexico hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 91: Mexico thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 92: Mexico thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 93: Mexico sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 94: Mexico sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 95: Mexico other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 96: Mexico other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 97: MEA hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 98: MEA thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 99: MEA thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 100: MEA sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 101: MEA sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 102: MEA other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 103: MEA other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 105: South Africa hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
  • TABLE 106: South Africa thalassemia market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 107: South Africa thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 108: South Africa sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 109: South Africa sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
  • TABLE 110: South Africa other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
  • TABLE 111: South Africa other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)

List of Figures

  • FIG. 1: Hemoglobinopathies : Market segmentation
  • FIG. 2: Hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 3: Hemoglobinopathies : Market dynamics
  • FIG. 4: Prevalence of hemoglobinopathies gene carriers
  • FIG. 5: Key opportunities prioritized: Type segment
  • FIG. 6: Hemoglobinopathies market - Porter's analysis
  • FIG. 7: Hemoglobinopathies market PESTEL analysis
  • FIG. 8: Unmet needs analysis: Hemoglobinopathies market
  • FIG. 9: Hemoglobinopathies market share, by therapy, 2014 & 2022
  • FIG. 10: Thalassemia therapy market, 2012 - 2022 (USD Million)
  • FIG. 11: Alpha thalassemia therapy market, 2012 - 2022 (USD Million)
  • FIG. 12: Beta thalassemia therapy market, 2012 - 2022 (USD Million)
  • FIG. 13: Sickle Cell Disease (SCD) market, 2012 - 2022 (USD Million)
  • FIG. 14: Other haemoglobin variants market, 2012 - 2022 (USD Million)
  • FIG. 15: Hemoglobinopathies market share, by diagnosis, 2014 & 2022
  • FIG. 16: Thalassemia diagnosis market, 2012 - 2022 (USD Million)
  • FIG. 17: Alpha thalassemia diagnosis market, 2012 - 2022 (USD Million)
  • FIG. 18: Beta thalassemia therapy market, 2012 - 2022 (USD Million)
  • FIG. 19: Sickle Cell Disease (SCD) market, 2012 - 2022 (USD Million)
  • FIG. 20: Other hemoglobin variants market, 2012 - 2022 (USD Million)
  • FIG. 21: Hemoglobinopathies market share by region, 2014 & 2022
  • FIG. 22: North America hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 23: U.S. hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 24: Canada. hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 25: Europe hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 26: UK hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 27: Germany hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 28: Asia Pacific hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 29: Japan hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 30: China hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 31: Latin America hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 32: Brazil hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 33: Mexico hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 34: MEA hemoglobinopathies market, 2012 - 2022 (USD Million)
  • FIG. 35: South Africa hemoglobinopathies market, 2012 - 2022 (USD Million)
Back to Top